journal article·2018-08

Automated Expansion of Primary Human T Cells in Scalable and Cell‐Friendly Hydrogel Microtubes for Adoptive Immunotherapy

Haishuang Lin, Qiang Li, Ou Wang, Jack Rauch, Braden Harm, Hendrik J. Viljoen, Chi Zhang, Erika Van Wyk, Chi Zhang, Yuguo Lei

Advanced Healthcare Materials· Volume 7· Issue 15
Publisher page

Abstract

Abstract Adoptive immunotherapy is a highly effective strategy for treating many human cancers, such as melanoma, cervical cancer, lymphoma, and leukemia. Here, a novel cell culture technology is reported for expanding primary human T cells for adoptive immunotherapy. T cells are suspended and cultured in microscale alginate hydrogel tubes (AlgTubes) that are suspended in the cell culture medium in a culture vessel. The hydrogel tubes protect cells from hydrodynamic stresses and confine the cell mass less than 400 µm (in radial diameter) to ensure efficient mass transport, creating a cell‐friendly microenvironment for growing T cells. This system is simple, scalable, highly efficient, defined, cost‐effective, and compatible with current good manufacturing practices. Under optimized culture conditions, the AlgTubes enable culturing T cells with high cell viability, low DNA damage, high growth rate (≈320‐fold expansion over 14 days), high purity (≈98% CD3+), and high yield (≈3.2 × 108 cells mL−1 hydrogel). All offer considerable advantages compared to current T cell culturing approaches. This new culture technology can significantly reduce the culture volume, time, and cost, while increasing the production.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: CAR-T cell therapy research · Viral Infectious Diseases and Gene Expression in Insects · Immune Cell Function and Interaction

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical and Biomolecular Engineering University of Nebraska Lincoln 68588 NE USA

Biomedical Engineering Program University of Nebraska Lincoln 68588 NE USA

Department of Radiation Oncology College of Medicine University of Nebraska Medical Center Omaha 68198 NE USA

CellGro LLC Lincoln 68506 NE USA

School of Biological Science University of Nebraska Lincoln 68588 NE USA

Mary and Dick Holland Regenerative Medicine Program University of Nebraska Medical Center Omaha 68198 NE USA

Fred & Pamela Buffett Cancer Center University of Nebraska Medical Center Omaha 68106 NE USA

References (64)

Show source-provided references
1. 10.1126/science.aaa496710.1126/science.aaa4967 ↗
2. 10.1126/science.125110210.1126/science.1251102 ↗
3. 10.1126/science.107651410.1126/science.1076514 ↗
4. 10.1200/JCO.2014.58.909310.1200/JCO.2014.58.9093 ↗
5. 10.1146/annurev-immunol-032713-12013610.1146/annurev-immunol-032713-120136 ↗
6. 10.1182/blood-2010-04-28193110.1182/blood-2010-04-281931 ↗
7. 10.1042/BST2015024010.1042/BST20150240 ↗
8. T.Hagen Novartis sets a price of $475 000 for CAR T‐cell therapy http://www.onclive.com/web‐exclusives/novartis‐sets‐a‐price‐of‐475000‐for‐car‐tcell‐therapy(accessed: August2017).
9. Wang X. · Mol. Ther. · 2016 · 3 · 1
10. 10.1038/cgt.2014.8110.1038/cgt.2014.81 ↗
11. 10.1016/j.coph.2015.08.00610.1016/j.coph.2015.08.006 ↗
12. Brentjens R. J. · Cancer Immunother. · 2013 · 5 · 177ra38
13. Kalos M. · Leukemia · 2011 · 3 · 95ra73
14. 10.1016/S0140-6736(14)61403-310.1016/S0140-6736(14)61403-3 ↗
15. 10.1056/NEJMoa110384910.1056/NEJMoa1103849 ↗
16. 10.1056/NEJMoa140722210.1056/NEJMoa1407222 ↗
17. Novartis receives first ever FDA approval for a CAR‐T cell therapy KymriahTM(tisagenlecleucel CTL019) for children and young adults with B‐cell ALL that is refractory or has relapsed at least twice https://www.novartis.com/news/media‐releases/novartis‐receives‐first‐ever‐fda‐approval‐car‐t‐cell‐therapy‐kymriahtm‐ctl019(accessed: August2017).
18. 10.1158/1078-0432.CCR-14-142110.1158/1078-0432.CCR-14-1421 ↗
19. 10.1158/1078-0432.CCR-10-227510.1158/1078-0432.CCR-10-2275 ↗
20. Heffner L. T. · Blood · 2012 · 120 · 404210.1182/blood.V120.21.4042.4042 ↗
21. 10.1016/j.blre.2015.10.00310.1016/j.blre.2015.10.003 ↗
22. 10.1182/blood-2009-03-21171410.1182/blood-2009-03-211714 ↗
23. 10.1200/JCO.2010.32.253710.1200/JCO.2010.32.2537 ↗
24. 10.1126/scitranslmed.300822610.1126/scitranslmed.3008226 ↗
25. 10.1200/JCO.2014.56.202510.1200/JCO.2014.56.2025 ↗
26. 10.1172/JCI8530910.1172/JCI85309 ↗
27. 1992 · 262
28. 10.1182/blood-2011-02-33736010.1182/blood-2011-02-337360 ↗
29. 10.1056/NEJMoa121513410.1056/NEJMoa1215134 ↗
30. 10.1038/gt.2008.18910.1038/gt.2008.189 ↗
31. 10.1016/j.ymthe.2005.07.68810.1016/j.ymthe.2005.07.688 ↗
32. 10.4161/onci.2120610.4161/onci.21206 ↗
33. 10.1186/1479-5876-10-6910.1186/1479-5876-10-69 ↗
34. 10.1038/cgt.2015.510.1038/cgt.2015.5 ↗
35. 10.1097/CJI.0b013e318194a6e810.1097/CJI.0b013e318194a6e8 ↗
36. 10.1038/mtm.2014.1510.1038/mtm.2014.15 ↗
37. 10.1097/CJI.0b013e31824e801f10.1097/CJI.0b013e31824e801f ↗
38. 10.1038/cgt.2014.7810.1038/cgt.2014.78 ↗
39. Kumaresan P. · J. Vis. Exp. · 2015 · 104 · 1
40. 10.1111/trf.1339410.1111/trf.13394 ↗
41. 10.1016/j.jcyt.2015.03.61110.1016/j.jcyt.2015.03.611 ↗
42. 10.1002/cite.20120017510.1002/cite.201200175 ↗
43. 10.1016/j.jcyt.2016.05.00910.1016/j.jcyt.2016.05.009 ↗
44. 10.1073/pnas.130940811010.1073/pnas.1309408110 ↗
45. 10.1007/s12195-014-0333-z10.1007/s12195-014-0333-z ↗
46. 10.1038/srep3191510.1038/srep31915 ↗
47. 10.1002/term.29110.1002/term.291 ↗
48. Kropp C. · Process Biochem. · 2016 · 10842 · 1
49. Gr M. · Blood · 2017 · 128 · 1270
50. 10.1016/j.jim.2010.02.00410.1016/j.jim.2010.02.004 ↗
51. 10.1038/nprot.2006.510.1038/nprot.2006.5 ↗
52. 10.1089/ten.teb.2011.004010.1089/ten.teb.2011.0040 ↗
53. 10.1186/scrt13610.1186/scrt136 ↗
54. 10.1016/j.scr.2014.02.00210.1016/j.scr.2014.02.002 ↗
55. 10.1016/j.stem.2013.12.00510.1016/j.stem.2013.12.005 ↗
56. 10.1371/journal.pone.010649310.1371/journal.pone.0106493 ↗
57. 10.1002/biot.20140034810.1002/biot.201400348 ↗
58. 10.1016/j.tibtech.2012.03.00310.1016/j.tibtech.2012.03.003 ↗
59. 10.1038/nbt.161610.1038/nbt.1616 ↗
60. 10.1016/j.stemcr.2014.09.01710.1016/j.stemcr.2014.09.017 ↗
61. 10.1016/j.scr.2015.08.00210.1016/j.scr.2015.08.002 ↗
62. 10.1016/j.progpolymsci.2011.06.00310.1016/j.progpolymsci.2011.06.003 ↗
63. 10.1002/biot.20130026210.1002/biot.201300262 ↗
64. 10.1038/srep4019110.1038/srep40191 ↗